Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
First for Women on MSN3d
Mia Hamm on Her Brother's Death + Advocating for Others (EXCLUSIVE)While many recognize Mia Hamm as a legendary soccer player and two-time Olympic gold medalist, she has also become a ...
Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback